VIRI is a 12/20 IPO developing a Fibromyalgia treatment with an FDA Fasttrack designation. A Ph2a POC study produced statistically significant data. This is the only program in their pipeline. VIRI filed to raise 30M by offering 3 Million shares. They burned $2.5M for the year in 2019. A Ph2b study is planned to optimize a dose to be used in a Ph3 study for longer-term chronic usage. The product is a combination of Famciclovir and Celecoxib. The opty may be in the Billions. Considering the questionable nature of many low-float stocks, this one seems to be a relatively attractive trading vehicle.